Patent application number | Description | Published |
20100285134 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND/OR THE PREVENTION OF OSTEOARTICULAR DISEASES - An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells. | 11-11-2010 |
20110027236 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOARTICULAR DISEASES - A pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases includes an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells. | 02-03-2011 |
20110064692 | HUMAN BONE-FORMING CELLS IN THE TREATMENT OF CONDITIONS AND BONE DISEASES ASSOCIATED WITH IMMUNODEFICIENCY OR IMMUNOSUPPRESSION - The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of diseases and conditions associated with immunodeficiency or immunosuppression. | 03-17-2011 |
20110262404 | Novel Mesenchymal Stem Cells and Bone-Forming Cells - The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 10-27-2011 |
20130084268 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND/OR THE PREVENTION OF OSTEOARTICULAR DISEASES - An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells. | 04-04-2013 |
20140093480 | Novel Mensenchymal Stem Cells And Bone-Forming Cells - The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 04-03-2014 |
20140100137 | MARKERS FOR IMPAIRED BONE FRACTURE HEALING - The present application discloses particularly interleukin-8 (IL-8) as a novel biomarker for the prediction, diagnosis, prognosis and/or monitoring of impaired bone fracture healing; and related methods, uses and kits. | 04-10-2014 |
20140212380 | TARGETS AND AGENTS FOR THE TREATMENT OF IMPAIRED BONE FRACTURE HEALING - The application teaches a composition comprising one or more pharmaceutical active ingredients selected from the group consisting of interleukin-8 (IL-8 or CXCL8), a functional fragment of IL-8, a functional variant of IL-8, and an agonist of IL-8 receptor, for therapeutic and/orprophylactic interventions in impaired bone fracture healing, such as but not limited to non-union fractures, mal-union fractures, or delayed union fractures. | 07-31-2014 |
Patent application number | Description | Published |
20100272696 | Human Bone-Forming Cells In The Treatment of Inflammatory Rheumatic Diseases - The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of inflammatory rheumatic diseases. | 10-28-2010 |
20100278788 | Osteogenic Differentiation Of Bone Marrow Stem Cells And Mesenchymal Stem Cells Using A Combination Of Growth Factors - The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 11-04-2010 |
20130266544 | Osteogenic Differentiation Of Bone Marrow Stem Cells And Mesenchymal Stem Cells Using A Combination Of Growth Factors - The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 10-10-2013 |
20140286916 | Uses of Growth and Differentiation Factor 8 (GDF-8) - The present invention relates to uses of growth and differentiation factor 8 (GDF-8) in vitro or in vivo for reducing the immunogenicity or risk of rejection of cells such as in particular mesenchymal stem cells (MSC), tissues or materials. The present invention further relates to methods for differentiating MSC in vitro or ex vivo into osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells using FGF-2 and GDF-8. In addition, the present invention relates to osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells obtainable by such methods and to the osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells for use in the treatment of musculoskeletal diseases. | 09-25-2014 |
20150238528 | Formulations Involving Solvent/Detergent-Treated Plasma (S/D Plasma) and Uses Thereof - The invention concerns pharmaceutical formulations comprising solvent/detergent (S/D)-treated plasma and a glycosaminoglycan such as hyaluronic acid, and their use for treating diseases, particularly musculoskeletal diseases. | 08-27-2015 |
Patent application number | Description | Published |
20090192696 | METHOD FOR EVALUATING THE QUANTITY OF FUEL INJECTED BY A FUEL INJECTOR IN AN INTERNAL COMBUSTION ENGINE, PARTICULARLY A DIESEL COMMON-RAIL ENGINE - A method is provided that includes, but is not limited to acquiring the crankshaft speed signal while one fuel injector is energized for a determined period of time (ET) in which all the other fuel injectors are de-energized, processing the acquired crankshaft speed signal so as to obtain signals or data (A) representative of the amplitude of a predetermined harmonic component of the crankshaft speed signal, and calculating the power (RMS/MS) of said harmonic component, and assuming the calculated power value (C) as an estimation of the quantity of fuel actually injected by the energized injector in said predetermined period of time (ET). | 07-30-2009 |
20110125389 | METHOD FOR THE DETERMINATION OF THE ACTUAL QUANTITY OF FUEL INJECTED IN AN INTERNAL COMBUSTION ENGINE - A method is provided for the determination of the actual quantity of fuel injected in an internal combustion engine, in particular a Diesel engine. The engine includes, but is not limited to an inlet line and an exhaust line, at least one cylinder and at least an injector for each of the cylinders. The method includes, but is not limited to, during a fuel cut-off state of the engine, at least an injection into one of the cylinders of a nominal fuel test quantity and, in correlation to the test injection, a determination of the air flow quantity MAF at the inlet of the engine, a determination of the parameter λ in the exhaust line of the engine, and a calculation of the actual quantity of fuel Q | 05-26-2011 |